About VentiRx
VentiRx is a Healthcare company based in Seattle (United States) founded in 2006, and was acquired by Celgene in October 2012. Small molecule TLR8 agonists are developed for cancer immunotherapy. VentiRx has raised $119.5 million across 5 funding rounds from investors including Celgene, Arch Venture Partners and Frazier Healthcare Partners. The company has 15 employees. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is VENTIRX PHARMACEUTICALS, INC. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
VentiRx Pharmaceuticals was founded in 2006 in Seattle, United States, focusing on the biotechnology sector. Novel therapeutics targeting Toll-like receptor 8 are developed and commercialized for oncology, respiratory, allergy, and autoimmuneinflammatory conditions. The lead asset, VTX-2337, a small molecule agonist, is evaluated in clinical trials combined with chemotherapies and monoclonal antibodies. A worldwide collaboration with Celgene Corporation supports this program.
- Headquarters Seattle, United States
- Employees 15
- Stage Acquired
- SectorsHealthcare
- Website ventirx.com
- Acquired by Celgene (Oct 2012)
- Legal Name Ventirx Pharmaceuticals, Inc.
Funding Insights of VentiRx
VentiRx has successfully raised a total of $119.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $119.5M
- Total Rounds 5
- Last Round Series B — $15M
- First Round $2.3M
(Feb 2007)
- Investors Count 5
All 5 funding rounds of VentiRx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2014 | $15M | Series B | – | – | – |
| Sep 2014 | $50.6M | Series B | – | Celgene | |
| Jan 2010 | $25M | Series A | – | – | |
| Mar 2007 | $26.6M | Series A | – | – | |
| Feb 2007 | $2.3M | Seed | – | – | – |
5 investors in total: 5 institutional.
Investors in VentiRx
VentiRx has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Celgene, Arch Venture Partners and Frazier Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
| medimmuneventures.com | ||||
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States |
Investor details for VentiRx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of VentiRx
13 people are tracked at VentiRx (10 in leadership, 3 in team); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
David Elkins | EVP & Chief Financial Officer | Leadership |
Ann M. Powell | EVP & Chief Human Resources Officer | Leadership |
Chris Boerner | EVP & COO | Leadership |
Cari Gallman | SVP & Chief Compliance & Ethics Officer | Leadership |
Robert Plenge | EVP, Chief Research Officer & Head of Research | Leadership |
Peter S. Paine III | SVP & Chief of Staff | Leadership |
Adam Lenkowsky | EVP & Chief Commercialization Officer | Leadership |
Giovanni Caforio | Chairman & CEO | Leadership |
Samit Hirawat | EVP & Chief Medical Officer, Global Drug Development | Leadership |
Greg Meyers | EVP & Chief Digital & Technology Officer | Leadership |
Sandra Leung | EVP & General Counsel | Team |
Elizabeth A. Mily | EVP, Strategy & Business Development | Team |
Estelle Vester-Blokland | SVP, Global Medical Affairs | Team |
Complete people profiles for VentiRx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of VentiRx
4 dated milestones of VentiRx across 8 years, from founding to its latest funding, stage changes and deals.
- Founded VentiRx is founded.
- Funding First funding round of $2.3M.
- Exit Acquired by Celgene.
- Funding Latest funding round, Series B, of $15.0M.
Competitors of VentiRx
VentiRx has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of VentiRx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as VentiRx (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ventirx
Complete news archive for VentiRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VentiRx
VentiRx was founded in 2006 and raised its 1st funding round 1 year after it was founded.
VentiRx is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
VentiRx is a funded company, having raised a total of $119.5M across 5 funding rounds to date. The company's 1st funding round was a Seed of $2.3M, raised on Feb 2007.
VentiRx has 15 employees.
VentiRx Pharmaceuticals was founded in 2006 in Seattle, United States, focusing on the biotechnology sector. Novel therapeutics targeting Toll-like receptor 8 are developed and commercialized for oncology, respiratory, allergy, and autoimmuneinflammatory conditions. The lead asset, VTX-2337, a small molecule agonist, is evaluated in clinical trials combined with chemotherapies and monoclonal antibodies. A worldwide collaboration with Celgene Corporation supports this program.
VentiRx's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
VentiRx has 5 investors. Key investors include Celgene, Arch Venture Partners, Frazier Healthcare Partners, Domain Associates, and MedImmune Ventures.
VentiRx operates through Ventirx Pharmaceuticals, Inc..
Yes. VentiRx was acquired by Celgene in October 2012.